IL-6 blockade in psoriatic arthritis — a new therapeutic option?
Crossref DOI link: https://doi.org/10.1038/nrrheum.2016.84
Published Online: 2016-05-24
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
FitzGerald, Oliver
Text and Data Mining valid from 2016-05-24
Article History
First Online: 24 May 2016
Competing interests
: The author declares that he has received consultancy, speaker's honoraria and research support from Abbvie, BMS, Celgene, Eli Lilly, Janssen, Novartis and Pfizer.